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IT was previously suggested (Currie and Bagshawe, 1967) that effective anti-
genic expression by some types of tumour cell may be inhibited by the presence
of sialic (N-acetylneuraminic) acid in the cell periphery. Treatment of the cells
from several " non-specific " transplantable mouse tumours with neuraminidase
results in a marked increase in their immunogenicity when subsequently injected
into intact host mice and leads to a powerful anti-tumour immunity in these
animals. So far this phenomenon has been reported using the Ehrlich (Linden-
mann and-Klein, 1967), Landschuitz (Currie, 1967), and TA3 (Sanford, 1967)
ascitic tumours. The antigenic discrepancies between these tumours and their
respective host mice are probably related to strain-specific histocompatibility
differences, i.e. these tumours are malignant allografts. Little ofthe information
obtained from the study of such tumours is ofimmediate relevance to the growth
and development of autochthonous tumours where the only tumour-host antigen
discrepancy (if any) is specific to the tumour.
The purpose of this paper is to report studies of the effects of incubation in
neuraminidase on the immunogenicity of chemically-induced tumour cells trans-
planted to mice of identical genotype; a situation in which a possible role for
sialic acidintheeffective expressionoftumourspecificantigenscanbeinvestigated.
MATERIALS AND METHODS
Mice.-All the animals used in this study were young adult male inbred CBA
strain mice. This mouse colony has been maintained by sib-sib mating in these
laboratories for five years and random skin-grafting has indicated that the colony
represents an immunologically homogeneous population. For use in these
experiments the mice were randomly distributed in polythene cages in groups of
five.
Tumours.-Tumours were induced by the subcutaneous injection of 3-methyl-
cholanthrene(MCA)inlightliquidparaffinintheinterscapularregion. Eachmouse
received 800 ,g. ofMCA suspended in 0-2 ml. of oil. Five tumours were utilised
in the present study and were the first five to appear. They were identified by the
prefix MC. The latentperiod between carcinogen administration andthe develop-
ment of a tumour 15 mm. in diameter was recorded for each tumour. Each
tumour was also examined histologically. The experiments were deliberately
designed to examine the growth and immunogenicity of cells from the original
tumour transplanted into syngeneic mice. Passage of tumour was minimised,
except where specified, to prevent the possible acquisition or deletion ofantigens.G. A. CURRIE AND K. D. BAGSHAWE
Cell suspensions.-When each tumour had reached 15 mm. diameter and was
free ofulceration or infection, the host mouse was killed by cervical dislocation and
the tumour excised under aseptic conditions. It was then washed in Hank's
balanced salt solution (HBSS) and finely chopped using two scalpel blades. For
the study of the first tumour (MCI) the fragments were triturated gently in a
loose fittingglass manualhomogeniser andthe resulting suspensionfiltered through
a double layer of cotton gauze. For the remaining four tumours the suspensions
were obtained by trypsinisation of the fragments in 0.1% Difco trypsin (1: 250)
in Dulbecco A solution for 30 minutes. The cell suspensions were then filtered
through gauze, centrifuged and washed in HBSS. Each suspension was examined
by trypan-blue staining to determine " viability " and the cell concentration
adjusted so that each 0-2 ml. contained 2 x 105 " viable " cells. A suspension
ofnormal spleen cells was obtained by gently forcing chopped and washed spleens
through a 21 gauge needle and allowing cell clumps and debris to settle out at
room temperature for 10 minutes. The decanted suspension of spleen cells was
examined by trypan-blue exclusion and the cell concentration adjusted to 2 x 105
viable nucleated spleen cells per 0-2 ml. HBSS.
Neuraminidase.-Cells were incubated in Vibrio cholerae neuraminidase
(Behringwerke, Batch 966c) at a concentration of 500 units/ml. in 0 05 M sodium
acetate-acetic acid buffered saline at pH 5-5 and containing calcium ions. Incu-
bation was performed at 370 C. for 30 minutes. After treatment all cells were
washed in HBSS three times and their trypan-blue exclusion viability counted.
Control cells were incubated under identical conditions in acetate buffer only.
Irradiation
Two groups of mice were irradiated in a closed perspex box using a 60Co
source. Total irradiation dose was 600 R. Twenty-four hours later one group
received 2 X 105 viable neuraminidase-treated sarcoma cells by intraperitoneal
injection and the other group received buffer-treated cells. Both groups were
observed for tumour development and the time of death recorded. Post-mortem
dissection was performed on each animal to confirm the presence ofintraperitoneal
tumour.
Intraperitoneal Injection
Groups ofnormal intact mice were given intraperitoneal injections of 2 x 105
dye-excluding neuraminidase-treated tumour cells from each sarcoma. Similar
groups of mice received the same number of buffer-treated cells. One group of
mice was given neuraminidase-treated normal syngeneic spleen cells, each mouse
again receiving 2 x 105 " viable " cells. All injected mice were observed daily
for the development ofintraperitoneal tumour and their survival in days recorded.
All mice which survived 50 days after inoculation were clinically tumour free
and those that were sacrificed showed no evidence oftumour either solid or ascitic.
Challenge
All the surviving tumour-free mice were challenged at Day 50 by the implan-
tation of a trocar fragment from the appropriate tumour into the right flank using
a 13 gauge trocar. Age matched untreated mice also received similar trocar
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fragments. The maximum diameter of the challenge tumours was measured
daily.
RESULTS
The results of the initial tumour inoculations are shown in Table I and the
rechallenge results are represented graphically in Fig. 1, 2 and 3. The results
for each sarcoma are described separately.
TABLE I.-Survival ofCBA Male MiceFollowing the Intraperitoneal Administration
of Neuraminidase-treated and Untreated Cells from Five Methylcholanthrene-
induced Syngeneic Sarcomas. The in vivo Development of Tumour was Inhib-
ited by the Neuraminidase Treatment in all the Tumours Except MC5.
Untreated
Intra-peritoneal
injection
MCi
MC2
MC3
MC4
MC5
First passage
Sixth passage
CBA spleen cells
MC4 injected into
irradiated mice
mm.
Dye exclusion
per cent
46
68
56
68
Survival ofmice
in days
43, 46, 46, 47, 49
24, 25, 30, 36, 37
26, 27, 30, 37, 40
18, 19, 20, 28, 30
71 15, 15, 16, 20, 20
68 18, 18, 18, 19, 19
95 >50
68 14, 14, 18, 19, 25
Neuraminidase treated
rx I
Viability ofinjected Survival ofmice
cells % dye exclusion in days
40 >50
64 >50
59 >50
66 >50
67
64
97
66
18, 22, 25, 27, 28
28, 29, 30, 30, 35
36, 37, 40, 42, 42
>50
27, 28, 34, 36, 37
MC2
10 20
DAYS
30 40 10 20
DAYS
FIG. 1.-Mean diameters of challenge tumours in mice which had previously received neura-
minidase treated cells from MC1 and MC2 and in control mice.
* 0 Tumours growing in normal control untreated mice.
* ------ * Growth of tumours in mice which had previously
receivedneuraminidase-treated cells.
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FIG. 2. Mean diameter ofgrowth ofchallenge implants ofMC3 and MC4 in treated and control
mice. Note the initial slow growth of the MC3 challenge followed by subsequent rapid
growth, greater than that in control mice.
*- 0 Tumours growing in normal control untreated mice.
*----- * Growth of tumours in mice which had previously
received neuraminidase-treated cells.
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FIG. 3. Mean diameters of challenge tumours. Left: The growth of MC1 implants in mice
which had previously resisted an injection of neuraminidase-treated MC4 cells compared
to growth in untreated control mice. Right; The growth of MC4 trocar implants in mice
which had previously received neuraminidase-treated syngeneic spleen cells.
* 0 Tumours growing in normal control untreated mice.
*------ * Growth of tumours in mice which had previously
received neuraminidase-treated cells.
mm.
40
301
20
10o.
o
30 40
144
.1
I
W""Iv
A I RTUMOUR SPECIFIC IMMUNOGENICITY
The data from the rechallenge experiments were tested for statistical significance
by comparing tumour diameters in the control and treated mice at two points in
time after the rechallenge inoculation. The mouse survival data from the MC5
experiment and MC4 injected into irradiated mice were also tested for significance
by comparing the survival of mice injected with treated cells to that of mice
given control cells. The significance test employed was the " t " test for compar-
ing uncorrelated means and the results are expressed as the probability value P.
MCI. The carcinogenetic latent period of this tumour was 96 days and
histological examination revealed that it was a well differentiated fibrosarcoma.
Neuraminidase-treated cells from this tumour failed to grow and the mice all
survived tumour-free, whereas the buffer-treated cells produced massive infiltra-
tion of the peritoneum, mesenteries and liver with finely nodular sheets of tumour
in all the injected mice. Trocar fragments of the tumour only grew very slowly
in the mice which had received neuraminidase-treated cells whereas control
untreated mice succumbed to rapidly growing massive subcutaneous sarcomas.
At Day 20 P < 0-02 and at the 40th day after rechallenge P < 0 01. In other
words, the administration of neuraminidase-treated MCI cells induced substantial
immunity to rechallenge with the same tumour. The initial cell suspension from
MCI was produced mechanically and consequently the dye-exclusion viability
of such cells was fairly low (46%). However such reduced viability did not
affect the ability ofuntreated tumour cells to grow when transplanted to syngeneic
hosts.
MC2.-The latent period ofthis tumour was 110 days. Histologically it was a
moderately well differentiated fibrosarcoma. Neuraminidase-treated cells did
not grow in the host mice and subsequent challenge with MC2 fragments after
50 days suggested the presence of a degree of immunity. Control buffer-treated
cells rapidly induced massive intraperitoneal tumour and death. Although the
immunised mice showed only slow growth of the trocar challenge tumour all the
mice in this group eventually developed massive abdominal wall tumours, presu-
mably at the initial tumour-cell injection site. These tumours did not appear
until about 40 days after the trocar challenge was administered. This phenom-
enon did not occur with any other tumour studied in this series. The mice which
died after intraperitoneal administration of buffer-treated MC2 cells showed no
evidence of such injection-site tumours.
Statistical evaluation of the difference between growth of the challenge tumour
in treated and control animals could only be performed at Day 20 as the data
from Day 40 are obviously complicated by the development of the injection site
tumours. The difference at Day 20 was only significant at the 200% level
(P < 0'2). Thus in this rather complex group it is difficult to evaluate the degree
of immunity (if any) conferred by the neuraminidase-treated cells.
1MC3. The latent period of this tumour was 121 days. Histological examina-
tion revealed a well differentiated fibrosarcoma. MC3 sarcoma cells, when
treated with neuraminidase, failed to induce tumour in all the recipient mice
whereas buffer-treated cells readily produced fatal solid intraperitoneal tumour.
When these surviving mice were challenged with MC3 fragments there was an
initial slow phase of tumour development for about 15-20 days. After 20 days
however the challenge tumours grew rapidly and eventually outgrew the tumours
implanted in control mice. The difference between the two groups at Day 10
was significant at the 10% level (P < 0-01). whereas at Day 20 there was no
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significant difference (P > 0.9). The reason for this initial apparent tumour-
immunity followed by rapid acceleration of tumour growth has not yet been
determined. However, the possibility ofimmunological enhancement supervening
in these apparently immune mice cannot be discounted.
MC4.-This tumour appeared after a latent period of 138 days. It was a
well differentiated fibrosarcoma. Acetate-buffer treated cells grew rapidly and
killed all the host mice within 30 days. Neuraminidase treatment of similar
cells prevented tumour growth. At both 20 and 35 days after inoculation the
difference was on the borderline of significance (0.05 < P < 0-1)
A similar group ofMC4-immune mice were challenged with fragments from MC1.
These tumours grew at exactly the same rate as MCI fragments in non-immune
control mice indicating that the immunity ofmice pretreated with neuraminidase-
treated MC4 cells was specific to MC4. (P> 0 9 atDay 20 andDay 40.) Another
group of mice was given intraperitoneal neuraminidase-treated syngeneic spleen
cells and challenged after 50 days with MC4. No effect on tumour growth was
detectable. (AgainP> 0 9onbothDay 20 andDay 40.)
Two groups ofmice irradiated with 600 r. received MC4 cells intraperitoneally.
Both control buffer-treated cells and neuraminidase-treated cells gave rise to
massive solid peritoneal tumour in these animals. However it is of interest to
note that the mean survival of mice injected with neuraminidase-treated cells
was substantially longer than those that received untreated cells (P < 0.01).
This was not significantly shorter than the survival of intact mice injected with
untreated cells (0.1 < P < 0.2).
MC5.-With a latent period of 145 days this tumour was a very poorly differ-
entiated anaplastic tumour probably of fibrous tissue origin. Neuraminidase
treatment of cells from this tumour did not prevent tumour development in any
of the injected mice in several repeated experiments. Mice were also injected
withneuraminidase-treated cells obtained bytrypsinisation ofMC5 after 6 passages
in syngeneic mice. Even after these passages the treatment did not prevent
subsequent death from tumour in all the inoculated mice. The survival time of
these mice however was longer than that found when the mice received the treated
cells from MC5 in the first passage, implying that there hadbeen some modification
of its growth characteristics during the passages. Although neuraminidase
treatment ofMC5 cells did not modify their ability to kill the mice there was some
prolongation in survival time (24 days compared to 17-2 days. P < 0-01) before
death from tumour occurred.
DISCUSSION
The antigenic properties ofchemically induced tumours arenowwellrecognised.
Foley (1953) has demonstrated that methylcholanthrene-induced sarcomas
growing in mice of identical genotype possess specific tumour antigens. Prehn
and Main (1957), Klein and co-workers (Klein et al., 1960), and Old and his
colleagues (Old et al., 1962) have extended these observations and have confirmed
that genetic heterogeneity of the mouse strains employed did not contribute to
the results and that immunological cross-reactions between tumours induced by
the same carcinogen were exceptional.
The results of the present study indicate that the cells from four out of five
methylcholanthrene-induced sarcomas show increased immunogenicity in syn-
geneic mice after incubation in neuraminidase. Intraperitoneal injection of
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2 x 105 untreated tumour cells produced massive solid tumours and death.
Incubation of similar cells in purified Vibrio cholerae neuraminidase prevented
the development of such tumours and subsequent challenge ofthe mice with trocar
fragments indicated the presence of detectable specific anti-tumour immunity.
Pretreatment of mice with neuraminidase-treated syngeneic spleen cells con-
ferred no immunity to trocar fragments of tumour indicating that the neuramini-
dase preparation used did not contain cross-reacting antigens and did not induce
cross-reaction with host mouse isoantigens. The anti-tumour immunity induced
was specific to the tumour used for immunisation.
In the design of these experiments the suspensions were prepared from the
original tumour before any passages had occurred and the challenge tumour was
taken from the tumour in its first passage in syngeneic mice. This precaution
was taken to minimise the possible occurrence of antigen-acquisition or deletion
in passage. In the case ofMC5, an apparently non-antigenic tumour, the experi-
ments were performed before and after 6 passages through syngeneic mice and
there was no evidence of significant antigenic acquisition. Another possible
source of error is the technique for producing the suspensions of cells. Old and
his colleagues (Old et al., 1962) have indicated that treatment of sarcoma cells
with trypsin may lead to errors, in that the serum of animals immunised with
trypsin-treated cells contains non-specific cytotoxins active against a wide range
of trypsin-treated target cells. This problem was overcome in two ways. The
cell suspension from MCI was prepared mechanically without trypsinisation but
still gave the same results as the other three trypsinised antigenic tumours. This
difficulty was also overcome by using trocar implanted tumour fragments as the
challenge dose to avoid effects due to non-specific cytotoxicity.
Any statement concerning the immunogenicity of a tumour is obviously
limited by the technique designed to detect it. Old and colleagues (Old et at.,
1962) have demonstrated that trocar implanted pieces of tumour are a relatively
insensitive means of detecting or quantitating weak immunity. Using graded
doses of cells in suspension they were able to detect immunity against apparently
non-antigenic tumours. It must be concluded therefore that neuraminidase-
treated cells from the first four sarcomas studied in this present series induced
substantial degrees of immunity. MC5 however apparently lacked appreciable
tumour specific immunogenicity after neuraminidase treatment. By examining
the growth curves of the rechallenge tumours compared to controls in each case,
it is apparent that the tumours that appeared earlier are more immunogenic
than the late ones. The immunogenicity of these tumours after neuraminidase
treatment appears to show a negative correlation with the length of the latent
period, i.e. the first tumour to appear was highly antigenic and the last was appar-
ently non-antigenic. These results are in accord with the hypothesis proposed by
Old et al., (1962) that the carcinogenetic latent period is the time when highly
antigenic malignant cells are eliminated and that tumours only appear when the
" growth potential " of the cells is capable of overcoming any immunological
restraints imposed on them.
What does the neuraminidase do to the tumour cells? It could be argued that
the effect of this enzyme on the immunogenicity of tumour cells is due to a toxic
effect which could either kill all the cells or retard their "growth potential "
and thus allow host immune responses to deal with them. The fortuitous appear-
ance ofan apparently non-antigenic tumour (MC.5) amongst those studiedprovides
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a means ofexploring these possibilities. Neuraminidase treatment had no effect
on the ability of MC5 cells to produce tumour and death occurred in all injected
host mice. This result supports the dye-exclusion viability data and confirm
that the enzyme is not cytotoxic. Similarly the growth of cells from an anti-
genic tumour (MC4) is not prevented by prior neuraminidase treatment when
they are injected into irradiated mice. In both these experiments however
there was some detectable prolongation of the survival of mice receiving neura-
minidase-treated cells. This could be due to an effect on "growth potential "
which is not associated with cell death. However it could also be explained in
other ways. The apparently non-antigenic tumour MC5 may in fact be weakly
antigenic, sufficient to cause a slight prolongation in mouse survival. Similarly
the irradiated mice receiving the enzyme-treated cells from MC4 may still have
been capable of mounting a weak immune response sufficient to delay tumour
growth but not to prevent it. Kraemer (1966) has studied the growth of Chinese
hamster ovary cells in tissue culture after treatment with neuraminidase, and
could detect no effect on cell replication. Recent studies in these laboratories
(Currie, 1968, unpublished) have shown that neuraminidase treatment of crude
cell wall fractions of the Landschutz ascites tumour produces a marked increase
in the immunogenicity of such fractions, implying that changes in "growth
potential" of treated cells do not have to be invoked to explain the effects of
this enzyme on tumour histocompatibility. However, the role of such hypo-
thetical changes has notyet beenfully elucidated and must be borne in mind when
explaining the results of the present studies. Further studies of the immuno-
genicity of intact and disrupted cells after various physical and chemical treat-
ments are in progress to determine the precise mode of action of neuraminidase
on tumour cells.
Neuraminidase catalyses the hydrolysis of 0-glycoside bonds and releases free
sialic (N-acetylneuraminic) acid from the surface of treated cells (Gottschalk,
1960). Previous studies ofthe Landschutz ascites tumour (Currie and Bagshawe,
1968), a malignant allograft, have suggested that cell surface neuraminidase
sensitive sialic acid may inhibit the cellular interactions involved in the detec-
tion and recognition of antigenic determinant molecular configurations and thus
diminish antigenic expression. The mechanism of this inhibition may well be
related to the steric properties of sialic acid bound by 2-6 0-glycoside bonds.
These studies of the effects of neuraminidase on chemically-induced sarcomas
transplanted to syngeneic mice suggest that this cell wall sialic acid may inhibit
the expression of tumour specific antigens. However, Foley (1953), Prehn and
Main (1957) and other workers (Old et al., 1962; Klein et al., 1960) have detected
the antigenicity of similar tumours without resorting to neuraminidase or other
chemical modifications of the cell wall. Untreated cells are immunogenic.
According to thehypothesisproposed by Old and his group (1962) there is, during
the development of tumours, a balance between antigenicity and "growth
potential ". Neuraminidase may well actby affecting this balance. By reducing
the cell wall sialic acid concentration it may increase the availability of antigenic
determinant areas to the host's antigen-reactive cells thus increasing the effective
immunogenicity of each tumour cell. Together with any effect on growth poten-
tial neuraminidase treatment would dramatically tip the balance towards anti-
genicity thus leading to immunological rejection of the cells and subsequent
specific tumour immunity.
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SUMMARY
The effects of incubation in neuraminidase on the immunogenicity of methyl-
cholanthrene-induced sarcoma cells transplanted to syngeneic mice have been
studied. The cells from 4 out of 5 sarcomas studied failed to develop in vivo after
incubation in Vibrio cholerae neuraminidase. When subsequently challenged
with tumour fragments the surviving mice showed substantial anti-tumour
immunity. The fifth tumour continued to grow and kill the host mice despite
neuraminidase treatment. The antigenicity of these 5 tumours appeared to
show a negative correlation with the length of the carcinogenetic latent period.
The neuraminidase preparation did not kill the cells, did not contain cross-
reacting antigens, nor did it induce cross reaction with syngeneic mouse spleen
cell isoantigens. Neuraminidase treated cells from an antigenic tumour grew
readily in mice irradiated with 600 r. It was concluded that neuraminidase
treatment caused an increase in the effective immunogenicity of tumour cells
in a situation where the only tumour-host antigenic discrepancy is tumour-specific.
The possible reasons for this increase are discussed.
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